Loading this company
Loading this company
Priced above our range of $23.37 to $69.61.
$85.98USD down −$0.06 (−0.07%)
Quoted · Prices are delayed.
This price comes from our backup market-data feed.
Nothing we can cite explains today’s move for this company.
Our range from 2 models, on today’s numbers
$23.37–$69.61
What the price needs: revenue growth of more than 25%/yr for 5 years (our model assumes 11.2%), or investors accepting a ~4.8% discount rate, vs the 11.8% our model uses.
Led by peer multiples (P/E, EV/EBITDA, P/S) · Fast grower
Delayed price used by the model $85.74Prices are delayed.
Our forward range over 12 months is part of Pro.
Try Pro free for 7 days — no card, auto-downgrade to Free.
Analysts’ mean target
$96.46 across 26 analysts
The high and low of the analyst range is part of Pro.
Try Pro free for 7 days — no card, auto-downgrade to Free.
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems for the management of diabetes and metabolic health in the United States and internationally. The company offers Dexcom G7 and G7 15 Day, an integrated continuous glucose monitoring system; Dexcom G6, a CGM system; Dexcom ONE+ to replace fingerstick blood glucose testing for diabetes treatment decisions; Stelo, a biosensor designed for adults with prediabetes and Type 2 diabetes who do not use insulin; Dexcom Share, a remote monitoring system; and Dexcom Follow application. It operates in the Medical Devices industry (Healthcare sector), headquartered in United States. The company employs roughly 11,000 people.
Revenue: United States 72% · International 28%
Prices are delayed. The feed does not say when these figures were taken.
No recent headlines we can cite for this company.
The 90-day buying-and-selling read is part of Pro.
Try Pro free for 7 days — no card, auto-downgrade to Free.
Not investment advice. TickerWorth Score is a model output.
Try Pro free for 7 days — no card, auto-downgrade to Free.
The score, the fair value and the reverse DCF are free on every company. Pro lets you change growth, margin and the discount rate yourself, see every valuation lens and its working, and download the model. Start a 7-day free trial — a card is required and you can cancel any time before it ends. $99 a year, or $14.99 monthly.